1. Use of rapid molecular tuberculosis diagnostics across Brazil’s incarcerated population
- Author
-
Elinor B. Fajer, Fernanda Dockhorn Costa, Daniele Maria Pelissari, Fredi Alexander Diaz Quijano, Artemir Coelho de Brito, Eunice Atsuko Totumi Cunha, Julio Croda, Jason R. Andrews, and Katharine S. Walter
- Subjects
Pediatrics ,medicine.medical_specialty ,education.field_of_study ,Tuberculosis ,business.industry ,Population ,Notifiable disease ,Newly diagnosed ,Molecular diagnostics ,medicine.disease ,World health ,Tuberculosis diagnostics ,medicine ,Sputum ,medicine.symptom ,education ,business - Abstract
BackgroundIncarcerated individuals in Brazil are at high-risk of tuberculosis (TB), but their access to World Health Organization recommended diagnostics is poorly understood.MethodsWe conducted a retrospective cross-sectional study of newly diagnosed TB cases in Brazil’s notifiable disease registry, which includes information on diagnostic tests performed, from January 2015 through December 2018. We quantified reported use of TB diagnostics across incarcerated and non-incarcerated populations and tested for municipality-level factors associated with diagnostic usage among the incarcerated population with generalized linear regression.ResultsBetween 2015 and 2018, 258,014 individuals were newly diagnosed with TB, including 27,400 (10.6%) incarcerated individuals. Among these, 27.5% had an Xpert MTB/RIF test reported; 71.5% had sputum smear; 34.1% had culture; 70.9% had chest radiography. Xpert MTB/RIF use was greater among incarcerated than non-incarcerated individuals (36.2% vs 26.5%, p5000) with rates of Xpert MTB/RIF usage below the national average in incarcerated individuals.ConclusionPrioritizing expansion of rapid molecular diagnostics in prisons, particularly in regions with limited current usage of molecular diagnostics, will be an essential component of TB control.
- Published
- 2021
- Full Text
- View/download PDF